VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
NEO
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
NEONeoGenomics, Inc.
$15.29$2.0B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
NEO logo

NeoGenomics, Inc.

NEO
NASDAQ · Diagnostics & Lab Testing
$15.29
At close - Nov 18, 4:00 PM EST - USD
Market Cap$1.97B
P/E-60.9x
52W High$20.15
Volume1.09M
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q3

Revenue Compounding Persists While Operating Losses Narrow Slowly

NeoGenomics continues to expand its top line, with revenue growing 11.4% year over year to $209.3M in 2026Q3, which suggests durable demand for its oncology testing services.

GrowthStable
ProfitabilityStrained
ValuationExpensive
TechnicalsMixed
Explore valuation models
MARKET ACTION

NEO price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

9/12 Beats

EPS beat 9 of last 12 quarters

02

Valuation risk

-310% Peers

P/E is 310% below peer median

03

Market leadership

RS 90 · Leader

High momentum (Outperforming 90% of market)

04

Mixed Trend

Mixed

Price < 50DMA but > 200DMA

Next CatalystEstimated earnings · Jan 28

Market performance

Price History →

Trailing total returns as of 11/19/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
NEO+30.02%
S&P 500 (^GSPC)+6.88%
1-Year Return
NEO+46.88%
S&P 500 (^GSPC)+10.62%
3-Year Return
NEO-21.63%
S&P 500 (^GSPC)+60.43%
5-Year Return
NEO-60.79%
S&P 500 (^GSPC)+60.87%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E
-60.9x
Forward P/E
75.8x
EV/EBITDA
125.8x
FCF YieldCash Flow
N/A

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
-60.9x
N/A
N/A
EV/EBITDA
125.8x
N/A
N/A
Price/FCF
N/A
N/A
N/A
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
Bear$5.44-64.4%
Base (Fair)$10.72-33.1%
Bull$13.11-14.3%
$5.44 Bear$10.72 Base$13.11 Bull
Current Market Price: $15.29
Trades at a 42.6% premium to Base DCF ($10.72)
Open DCF & Valuation Models →Chart Terminal ↗

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$727M+10.1% YoY
Net income FY25
-$108M-37.2% YoY
Free cash flow FY25
-$22M+36.0% YoY
Operating margin FY25
-9.1%+4.9 pts YoY
ROIC (FY25)-4.3%
Avg ROIC 5Y-6.7%
ROE (TTM)-4%
Piotroski Score5 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate9/12 (75%)
Revenue Beat Rate5/12 (42%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Oct 28, 2026
$0.07+26.2%
vs $0.06
$209M+1.2%
vs $207M
Q3 2026
Jul 28, 2026
$0.05+49.0%
vs $0.03
$202M+2.4%
vs $197M
Q2 2026
Apr 28, 2026
$0.01+73.0%
vs $0.01
$187M+1.2%
vs $185M
Q1 2026
Feb 17, 2026
$0.06+50.0%
vs $0.04
$190M+0.9%
vs $188M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
GlobeNewsWire·1d ago
NeOnc Reports Additional Partial Response in Phase 2a Study of Intranasal NEO100

Objective response rate was 12.5% (3 of 24 patients) by RANO 2.0, compared with 8.3% (2 of 24 patients) in the August topline results Median overall survival was 26.1 months from the start of NEO100 treatment at recurrence, as previously reported CALABASAS, Calif., Nov. 17, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) cancers, today reported updated interim results from the Phase 2a portion of NEO100-01, an open-label study of intranasal NEO100 in patients with recurrent or progressive Grade III or Grade IV IDH1-mutant glioma.

Business Wire·5d ago
Better Adds $43.7 Million in Volume Across Two Purchase-Focused Teams in California and the Mid-Atlantic Through NEO Home Loans Channel

NEW YORK--(BUSINESS WIRE)---- $BETR #BETR--Better Home & Finance Holding Company (NASDAQ: BETR) today announced that two established mortgage teams have joined NEO Home Loans, powered by Better. The Daniel Estrada Team is based in Bakersfield, California, and Team Neilsen serves Virginia, Washington, D.C., and Maryland. Both teams bring new purchase volume to Better and widen its reach in California's southern Central Valley and the Mid-Atlantic. The Daniel Estrada Team funded $23.7 million of mortgage vol.

GlobeNewsWire·Nov 11, 2026
FDA Meeting Could Put NeOnc's NEO100 Experimental Brain Cancer Drug on Faster Track

DENVER, Nov. 11, 2026 (GLOBE NEWSWIRE) -- ( 247MarketNews ) — NeOnc Technologies Holdings (NASDAQ: NTHI) secured a Type B End-of-Phase meeting, scheduled for early January 2027, with the U.S. Food and Drug Administration (FDA), to discuss a potential accelerated approval pathway for its experimental intranasal brain cancer treatment NEO100, putting the company's regulatory strategy in focus as it prepares for a randomized Phase 3 study. NeOnc intends to seek FDA feedback on whether its existing clinical and nonclinical evidence could support a 505(b)(2) New Drug Application (NDA) seeking accelerated approval for recurrent or progressive IDH-mutant grade 4 astrocytoma.

GlobeNewsWire·Nov 11, 2026
NeOnc Technologies Granted FDA Type B End-of-Phase Meeting to Discuss Potential Accelerated Approval Pathway and Phase 3 Confirmatory Trial for Intranasal NEO100

CALABASAS, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company a Type B End-of-Phase meeting to discuss a potential accelerated approval pathway for intranasal NEO100 in recurrent or progressive IDH-mutant grade 4 astrocytoma.

Filtered for NeoGenomics, Inc.More Headlines
04

Compare before deciding

Benchmark NEO against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for NeoGenomics, Inc. (NEO)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
NEO logoNEONeoGenomics, Inc.Current
$15.29$1.97B-60.8710.11%-4.1%-3.97%—
CDNA logoCDNACareDx, Inc
$74.44$3.85B31.8213.79%25.86%34.08%—
NTRA logoNTRANatera, Inc.
$289.50$41.46B-253.2135.9%-5.66%-9.18%—
LH logoLHLabcorp Holdings Inc.
$370.78$30.4B30.147.25%6.88%11.52%0.77%
DGX logoDGXQuest Diagnostics Incorporated
$259.69$28.66B25.7611.78%9.53%14.66%1.2%
MYRG logoMYRGMYR Group Inc.
$272.21$4.24B22.158.79%4.48%26.32%—

Compare NEO vs Peers

NeoGenomics, Inc. (NEO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs CDNA

Most directly comparable listed peer for NEO.

Scale Benchmark

vs TMO

Larger-name benchmark to compare NEO against a more recognizable public peer.

Peer Set

Compare Top 5

vs CDNA, NTRA, LH, DGX

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

NEO SEC Filings & Documents

NeoGenomics, Inc. (NEO) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Oct 28, 2026·SEC

Material company update

Oct 5, 2026·SEC

Material company update

Jul 28, 2026·SEC

10-K Annual Reports

3
FY 2026

Feb 17, 2026·SEC

FY 2025

Feb 18, 2025·SEC

FY 2024

Feb 20, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Oct 28, 2026·SEC

FY 2026

Jul 28, 2026·SEC

FY 2026

Apr 28, 2026·SEC

Get notified when NEO posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

NEO Frequently Asked Questions

NeoGenomics, Inc. (NEO) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is NeoGenomics, Inc.'s revenue?

NeoGenomics, Inc. (NEO) reported $787.8M in revenue over the trailing twelve months. Revenue was $727.3M in fiscal year 2025. That is 288063% more than the $0.3M of fiscal year 2000.

How fast is NeoGenomics, Inc. growing?

NeoGenomics, Inc. (NEO) grew revenue by 11.1% over the trailing twelve months, compared with the twelve months before.

Is NEO profitable?

No. NeoGenomics, Inc. (NEO) reported a net loss of $32.3M over the trailing twelve months.

Dividend & Returns
What is NEO's return on equity?

NeoGenomics, Inc. (NEO) had a return on equity (ROE) of -4.0% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is NeoGenomics, Inc.'s free cash flow?

NeoGenomics, Inc. (NEO) had negative free cash flow of $28.6M over the trailing twelve months.

What if you invested $1,000 in NEO back in 2000?

Total return calculator · dividends reinvested · 26+ years of data

See returns →